





A unit of Artemis Medicare Services Ltd.

### **February 5, 2025**

The Secretary,
National Stock Exchange of India Limited
Exchange Plaza, Bandra-Kurla Complex,
Bandra (E),
Mumbai – 400 051

The Secretary, BSE Limited Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai – 400 001

NSE Code: ARTEMISMED Scrip Code: 542919

**Sub:** Press Release

Dear Sir/Ma'am,

With reference to the captioned subject, please find attached herewith a press release titled "Artemis Consolidates its Performance with YoY Growth in Financial and Operational Metrics, Reporting Highest ever ARPOB, Continued Focus on Tower 3 Ramp up and Expansion Strategy", being issued by the Company.

Submitted for your information & records.

Thanking you.

Yours Faithfully,
For Artemis Medicare Services Limited

Poonam Makkar Company Secretary & Compliance Officer

Encl.: As above













# Artemis Consolidates its Performance with YoY Growth in Financial and Operational Metrics, Reporting Highest ever ARPOB Continued Focus on Tower 3 Ramp up and Expansion Strategy

## Q3 FY25 Consolidated Gross Revenue of INR 2,431 Mn; up 6.3% Y-o-Y Q3 FY25 EBITDA of INR 463 Mn; up 34.4% Y-o-Y Q3 FY25 PAT of INR 206 Mn; up 78.3% Y-o-Y

**New Delhi, February 05, 2025**: Artemis Medicare Services Ltd. ("Artemis" or the "Company") (BSE: 542919 | NSE: ARTEMISMED) announced its Q3 and 9M FY25 results. The Company operates 800+ beds predominantly in the Delhi NCR region, including a 700+ bed quaternary care, super speciality hospital accredited by JCI and NABH. Additionally, the Company runs a JV with Philips under the Artemis Cardiac Care brand. Artemis also has overseas presence in Mauritius through an operations and management arrangement.

#### Artemis Hospital Gurgaon Performance Highlights Q3 FY25 vs Q3 FY24

- Average gross revenue per occupied bed (ARPOB) of INR 80,200 compared to INR 77,900
- Net Revenue from Operations increased by 7.5% to INR 2,171 Mn from INR 2,019 Mn
- EBITDA margin at 21.4% compared to 18.2%
- Bed capacity utilisation, including that for the new tower stood consistent at 60.4%
- Revenues from overseas patients increased by 11.6% to INR 649 Mn from INR 581 Mn
- Overseas patients contributed 30% to Net Revenue
- Patient footfall of 91,673 and 3,215 surgeries performed
- Average length of stay (ALOS) at 3.70 days compared to 3.81 days

#### Consolidated Performance Highlights Q3 FY25 vs Q3 FY24

- Net Revenue from Operations increased by 6.2% to INR 2,324 Mn from INR 2,188 Mn
- EBITDA increased by 34.4% to INR 463 Mn from INR 344 Mn
- EBITDA margin at 19.9% compared to 15.7%
- PBT increased by 64.4% to INR 268 Mn from INR 163 Mn with margin of 11.5%
- PAT increased by 78.3% to INR 206 Mn from INR 116 Mn, with margin of 8.9%

#### **Consolidated Performance Highlights 9M FY25 vs 9M FY24**

- Net Revenue from Operations increased by 6.7% to INR 6,970 Mn from INR 6,533 Mn
- EBITDA increased by 36.3% to INR 1,365 Mn from INR 1,002 Mn, with margin of 19.6% over 15.3%
- PAT increased by 70.1% to INR 593 Mn from INR 348 Mn, with margin of 8.5% over 5.3%



### Announcing the results, Dr. Devlina Chakravarty, Managing Director of Artemis Medicare Services Ltd, commented:

"The company has delivered a robust performance in Q3 FY25 and 9M FY25, driven by our unwavering focus on improving key business metrics and operational efficiencies. Despite this being a seasonally muted quarter, we have been able to achieve YoY growth and posted highest ever ARPOB by optimising the payer mix. Additionally, our increasing revenue contribution from international patients underscores our prominence as a preferred destination for Medical Value Travel. To cater to our growing customer base, we are focusing on ramping up the occupancy in the third tower. With this, we expect to further improve our performance by leveraging economies of scale and improving cost efficiencies.

During the quarter, we have taken initiatives to enhance operational efficiencies by removing bottlenecks in the processes and improving patient experience. We have also announced advanced tech-driven physiotherapy services in a strategic tie-up with Abhinav Bindra Targeting Performance (ABTP), aiming to revolutionise patient care by offering tailor made services.

Aligned with our strategic growth initiatives, we are streamlining our efforts to launch operations at our recently announced Raipur facility within the next year, marking our access into central India. Furthermore, we continue to explore expansion opportunities in the super-speciality segment, allowing us to strengthen our brand, expand our footprint, and achieve our growth plans."

#### For further information, please contact:

Sanjiv K Kothari, Chief Financial Officer Artemis Medicare Services Ltd.

+91 124 4511 111
Sanjiv.kothari@artemishospitals.com

Simran Malhotra / Anvita Raghuram Churchgate Partners

+91 22 6169 5988 Artemisteam@churchgatepartners.com

This press release may include statements of future expectations and other forward-looking statements based on management's current expectations and beliefs concerning future developments and their potential effects upon Artemis Medicare Services Ltd and its subsidiaries/ associates. These forward-looking statements involve known or unknown risks and uncertainties that could cause actual results, performance or events to differ materially from those expressed or implied in such statements. Important factors that could cause actual results to differ materially from our expectations include, amongst others: general economic and business conditions in India and overseas, our ability to successfully implement our strategy, our research and development efforts, our growth and expansion plans and technological changes, changes in the value of the Rupee and other currency changes, changes in the Indian and international interest rates, change in laws and regulations that apply to the related industries, increasing competition in and the conditions of the related industries, changes in political conditions in India and changes in the foreign exchange control regulations in India. Neither Artemis Medicare Services, nor our directors, or any of our subsidiaries/associates assume any obligation to update any forward-looking statement contained in this release.